Capstan Therapeutics reported data on a novel in vivo engineering approach that uses targeted lipid nanoparticles (LNPs) to deliver mRNA encoding chimeric antigen receptors (CARs) directly to T-cell populations, circumventing complex ex vivo manufacturing steps. This method aims to generate functional CAR T cells within the patient, enhancing accessibility and scalability for the treatment of B-cell malignancies and autoimmune diseases. This approach may reduce the need for lymphodepletion and streamline CAR T therapy production compared to traditional methods.